The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome

Objective. Based on a retrospective cohort study, to investigate the value of rivaroxaban combined with ticagrelor in antithrombotic therapy after PCI in patients with nonvalvular atrial fibrillation with acute coronary syndrome. Methods. A total of 60 patients from January 2019 to May 2021 accepted...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2022, Vol.2022, p.4807175-7
Main Authors: Liu, Zhengwang, Qiu, Xiaotang, Yang, Hua, Wu, Xiaocui, Ye, Wenjing, Zheng, Xinbing
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Adenosine diphosphate
Angina
Angina pectoris
Angioplasty
Anticoagulants
Blood flow
Blood platelets
C-reactive protein
Calcium-binding protein
Cardiac arrhythmia
Cardiovascular disease
Clinical medicine
Cohort analysis
Coronary vessels
Creatine
Creatine kinase
Drug interactions
Embolisms
Fibrillation
Flow velocity
Heart attacks
Ischemia
Kinases
Metabolism
Myocardial infarction
Patients
Pharmacokinetics
Platelet aggregation
Polymorphism
Statistical analysis
Thrombosis
Troponin
Troponin I
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. Based on a retrospective cohort study, to investigate the value of rivaroxaban combined with ticagrelor in antithrombotic therapy after PCI in patients with nonvalvular atrial fibrillation with acute coronary syndrome. Methods. A total of 60 patients from January 2019 to May 2021 accepted therapy with antithrombotic therapy after PCI. The patients treated with ticagrelor were set as the control group, and those given rivaroxaban combined with ticagrelor were set as the research group. The curative effect, myocardial level, TIMI blood flow grade, platelet aggregation rate, and the incidence of cardiovascular events were taken from the comparisons. Results. The research group’s therapeutic impact was superior to the control group’s therapeutic impact, and the value was higher. After treatment, the myocardial levels of the two groups decreased, and the levels of troponin I, creatine kinase isoenzyme, and hypersensitive C-reactive protein in the research group were greatly less than those in the control group, and the difference was statistically significant (P
ISSN:1741-427X
1741-4288
DOI:10.1155/2022/4807175